CLINUVEL PHARMACEUTICALS LTD

CLINUVEL PHARMACEUTICALS LTD Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from CLINUVEL PHARMACEUTICALS LTD, Medical and health, 535 Bourke Street, Melbourne.

CLINUVEL is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations.

On , we reaffirm CLINUVEL’s mission to deliver science-driven solutions that improve individuals’ quality of life and d...
07/04/2026

On , we reaffirm CLINUVEL’s mission to deliver science-driven solutions that improve individuals’ quality of life and deliver effective treatment where it’s needed most.

We appreciate the significance of being able to function in good health and we value this gift every day.

29/03/2026

The final day at the Pavilion of Photomedicine was one to remember! Thank you to everyone who has visited us over the last 3 days to discover the science behind the CLINUVEL story and how we are advancing care for patients with vitiligo and EPP.

Today, we were joined by Shahnawaz Towheed for a conversation on vitiligo and Dr Faranak Kamangar and Dr Hannah Wanyika shared highlights from the ongoing CUV105 vitiligo trial.

Our team was equally inspired by the day’s scientific sessions — including an in-depth discussion of new vitiligo data and The Skin of Color Symposium.

The Pavilion doors may be closed, but the CLINUVEL team will be attending the scientific sessions during the final days of , sharing more highlights across our social channels.


28/03/2026

The conversation on innovation and advancing patient care continued at the Pavilion of Photomedicine on day 2 of .

The CLINUVEL team were joined by guest speaker George Hodder for an in-depth discussion of navigating life with the rare disorder EPP.

An inspiring and emotive panel discussion on psychodermatology with Tonja Johnson, Reuben K. Sam and Professor Antoine Bertolotti also took place today, highlighting the importance of treating vitiligo with a holistic approach.

If you haven’t already experienced the Pavilion of Photomedicine, we hope to see you here tomorrow on the last day for the exhibit!


28/03/2026

We’re back for day 2 of .

The CLINUVEL team will be welcoming more guests to the Pavilion of Photomedicine, while also attending a number of scientific sessions at the Colorado Convention Centre.

A key session taking place today is focused on vitiligo, with Dr Seemal R. Desai exploring chemicals that induce vitiligo and Dr Khaled Ezzedine covering common, uncommon, and rare presentations of vitiligo.

Dr Pearl Grimes, will be joining Dr Desai and Dr Ezzedine for a Q&A based on the vitiligo session.

Also on today’s program are sessions exploring inflammatory skin diseases in skin of colour, the science of cosmeceuticals and nutraceuticals, and ‘Pigmentary Potpourri’ featuring a presentation by Dr. Nada Elbuluk.

At the Pavilion of Photomedicine, we will be joined by guest speaker George Hodder to share his journey of navigating life with EPP and a panel discussion on psychodermatology with Tonja Johnson, Reuben Sam and Professor Antoine Bertolotti.


27/03/2026

Welcome to the Pavilion of Photomedicine.

Our doors are now open at and we’re welcoming all attendees to visit the Pavilion to discover the innovative science behind CLINUVEL’s success and how the Company plans to advance care for people living with conditions such as vitiligo and erythropoietic protoporphyria (EPP).

Today, we will be joined by Nurse Kelly Robinson for a candid discussion on the importance of patient engagement.

Find the Pavilion of Photomedicine at exhibition space 4131 within the Colorado Convention Center.



CLINUVEL today revealed its expansive program for the 2026 American Academy of Dermatology (AAD) Annual Meeting taking p...
27/03/2026

CLINUVEL today revealed its expansive program for the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver from 27–31 March.

The Company’s work features heavily across academic presentations, exhibitions and events, with a focus on the development of afamelanotide to treat vitiligo and SCENESSE® (afamelanotide), the only FDA-approved treatment for patients with the rare disorder erythropoietic protoporphyria (EPP).

Learn more about CLINUVEL at AAD 2026 here:https://www.clinuvel.com/wp-content/uploads/2026/03/20260327-clinuvels-global-programs-showcased-at-aad.pdf


Congratulations to Prof A Bertolotti for an excellent presentation of case reports from the ongoing CUV105 study with ...
27/03/2026

Congratulations to Prof A Bertolotti for an excellent presentation of case reports from the ongoing CUV105 study with afamelanotide at this morning's Global Vitiligo Foundation (GVF) Annual Symposium.

Based on the Q&A it seems some in the derm community are behind in their knowledge of melanocortins, so we thought this 2018 paper may help: https://pubmed.ncbi.nlm.nih.gov/30205559/

At CLINUVEL, we believe that breakthrough treatments are born from rigorous scientific exchange. We are pleased to be ab...
26/03/2026

At CLINUVEL, we believe that breakthrough treatments are born from rigorous scientific exchange.

We are pleased to be able to support the scientific meetings of three key organisations within the field of photodermatology.

The 35th Annual Meeting of the Photodermatology Society is focused on understanding the impact of light in health and sciences. Dr Robert Gadow’s poster presentation on a two-year follow-up of erythropoietic protoporphyria (EPP) patients during afamelanotide treatment will be on display at the event.

The Global Vitiligo Foundation Annual Scientific Symposium unites the vitiligo expert community to share key updates and celebrate the work of the foundation.

And the 22nd Annual Skin of Color Society Scientific Symposium explores topics centred on treating diverse skin types.


CLINUVEL is proud to welcome Dr Faranak Kamangar to the Pavilion of Photomedicine at AAD 2026.Dr Kamangar will present l...
23/03/2026

CLINUVEL is proud to welcome Dr Faranak Kamangar to the Pavilion of Photomedicine at AAD 2026.

Dr Kamangar will present learnings from CUV105, CLINUVEL’s ongoing clinical trial investigating a potential systemic repigmentation treatment for individuals with vitiligo.

Don’t miss this opportunity to hear her perspective on the trial, the underlying research and more about the evolving landscape of vitiligo treatment.

CLINUVEL will be attending WIRED Health 2026 in London on 16 April 2026. This one-day event will bring together some of ...
17/03/2026

CLINUVEL will be attending WIRED Health 2026 in London on 16 April 2026.

This one-day event will bring together some of the brightest minds in healthcare, from disruptors to scientists and entrepreneurs, all focused on shaping the future of the industry.

We’re delighted that our Managing Director, Dr Philippe Wolgen, will be discussing the future of self-bronzing at the event.
Discover how CLINUVEL is translating our groundbreaking melanocortin science into a cosmetic revolution at WIRED Health 2026.

Purchase your tickets here: https://health.wired.com/

With our ongoing CUV105 clinical trial, CLINUVEL is investigating a new, systemic repigmentation treatment for people li...
16/03/2026

With our ongoing CUV105 clinical trial, CLINUVEL is investigating a new, systemic repigmentation treatment for people living with vitiligo.

We are excited to announce that Dr Hannah Wanyika, a renowned dermatology expert working on the trial, will join us in Denver for , sharing key insights from CUV105.

Visit the Pavilion of Photomedicine during AAD to hear from Dr Wanyika and more guest speakers on topics such as vitiligo, psychodermatology and our melanocortin technology.
Follow our channels for the latest updates!

Imagine a life with a rare metabolic disorder where any visible light causes you intense, phototoxic reactions.For peopl...
12/03/2026

Imagine a life with a rare metabolic disorder where any visible light causes you intense, phototoxic reactions.

For people like George Hodder, who live with erythropoietic protoporphyria (EPP), this is reality.

Children and adults living with EPP must avoid light and even reflected light for life, often having to stay indoors or wear protective clothing.

CLINUVEL is committed to treating EPP, with a focus on advocating and advancing care for patients worldwide. That is why we are honoured to invite George Hodder to share his story at , helping to foster greater understanding of this rare disease.

Address

535 Bourke Street
Melbourne, VIC
3000

Telephone

+61396604900

Website

Alerts

Be the first to know and let us send you an email when CLINUVEL PHARMACEUTICALS LTD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category